In conclusion, our study provides a novel insight into TAGLN/HDAC2‐promotion of cell cycle progression through deacetylation of p53 at K382 under hypoxia and offers a targeted approach to improve the therapeutic effect of GBM. The gene discussed is TP53; the disease is glioblastoma.